Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncolin Therapeutics, formerly known as Edgeline Holdings has agreed to the licensing terms for a key patent that involves the synthesis of 2-deoxy sugars and their derivatives.
Subscribe to our email newsletter
This enabling patent provides processes to synthesize compounds that would otherwise be difficult and expensive to prepare with high purity and steroselectivity. These compounds are the lead drugs in the company’s antimetabolite development program focused on the treatment of cancers, especially brain tumors.
Donald Picker, COO of Edgeline Holdings, said: “This program is currently being developed to initiate human clinical trials and therefore having a cost effective synthesis to the compounds is an important advantage for the timely development of these drugs.”